|
154 |
Why Isolators Do Not Automatically Ensure Annex 1 Compliance
|
관리자 |
2026-06-05 |
135 |
|
153 |
How Are Service Providers Qualified in a GDP Environment?
|
관리자 |
2026-06-05 |
146 |
|
152 |
CAPA and Root Cause Analysis - why FDA keeps calling them out
|
관리자 |
2026-06-05 |
135 |
|
151 |
Which GMP Requirements Apply to Stability Studies in the Pharmaceutical Industry?
|
관리자 |
2026-05-06 |
582 |
|
150 |
FDA's 483 Playbook: What It Means For Pharma Outsourcing — And What It Doesn't Address
|
관리자 |
2026-05-06 |
575 |
|
149 |
All The Ways Global Biopharma Still Grapples With Annex 1
|
관리자 |
2026-05-06 |
346 |
|
148 |
The Capacity Myth—and What Actually Matters
|
관리자 |
2026-02-27 |
970 |
|
147 |
Process Engineering's Key Role In Sterile Injectable Facility Design
|
관리자 |
2026-02-27 |
928 |
|
146 |
When Training Falls Short: FDA Findings on GMP Training Deficiencies in 2025
|
관리자 |
2026-02-27 |
634 |
|
145 |
How to Design Your Pharmaceutical Facility Disinfection Programme Cleanroom
|
관리자 |
2026-01-30 |
1,027 |
